U.S. Food et al., 2023: FDA safety-labeling-change record for the 2023 boxed warning adding opioids to the serotonin-syndrome warning for methylene blue.
PROVAYBLUE® may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.
U.S. Food et al., 2023: FDA safety-labeling-change record for the 2023 boxed warning adding opioids to the serotonin-syndrome warning for methylene blue. Application 204630, supplement 22, approved drug label at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204630s022lbl.pdf. The record states "Some of the reported cases were fatal." Recorded under F5 against the source's "rare/manageable/celebrate" framing. Study type: regulatory record.
